March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Transepithelial Corneal Crosslinking Methods: Femtosecond-Laser Pocket, Permeability Enhancers In Rabbits
Author Affiliations & Notes
  • Michelle P. Lin
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Brian Armstrong
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Ronald Krueger
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Marcony Santhiago
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Vivek Singh
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Vandana Agrawal
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Steven Wilson
    Ophthalmology, Cleveland Clinic, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  Michelle P. Lin, None; Brian Armstrong, None; Ronald Krueger, None; Marcony Santhiago, None; Vivek Singh, None; Vandana Agrawal, None; Steven Wilson, None
  • Footnotes
    Support  EY 10056 and Research to Prevent Blindness, New York, NY
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4125. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michelle P. Lin, Brian Armstrong, Ronald Krueger, Marcony Santhiago, Vivek Singh, Vandana Agrawal, Steven Wilson; Transepithelial Corneal Crosslinking Methods: Femtosecond-Laser Pocket, Permeability Enhancers In Rabbits. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4125.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To compare the effect of transepithelial delivery of riboflavin through a femtosecond laser-created intrastromal pocket or topical permeability enhancers with ultraviolet A (UVA) to traditional epithelium-off crosslinking on the corneal stromal cellular response and corneal stromal density in rabbits.

 
Methods:
 

Thirty-six rabbits underwent study. Animals were divided into three treatment groups and corneas were analyzed at 24 hours and 8 weeks postoperatively. Treatment groups were: 1) standard epithelium off CXR, 2) femtosecond laser pocket riboflavin delivery transepithelial CXR, and 3) permeability enhancer carboxymethylcellulose (CMC)/tetracaine transepithelial CXR. Crosslinking parameters used were 0.1% riboflavin, UVA (370nm) irradiance 3 mW/cm2, 30 minutes (Roisterer, Vienna, Austria). The TUNEL assay was performed to detect stromal cell apoptosis, and immunohistochemistry for the smooth muscle action (SMA) marker for myofibroblasts. Corneal density/haze was quantified using GALILEI Scheimpflug Analyzer (Ziemer, Alton, USA). GALILEI has a diagnostic feature that can measure the relative density from 0 - 100 over two axes (0 least, 100 most).

 
Results:
 

At 24 hours, the standard epithelium off CXR and femtosecond pocket transepithelial CXR methods had significantly more stromal cells apoptosis than permeability enhancer CMC/tetracaine transepithelial CXR. 147±8, 140±11, 3±0.5 per 400x power field, respectively (P<0.001). Permeability enhancer CMC/tetracaine transepithelial CXR triggered minimal apoptosis in anterior stroma. Minimal SMA+ myofibroblasts were detected in any group. At 8 weeks after CXR, femtosecond (71±3) and standard CXR (79±4) methods, generated more dense corneas than the permeability enhancer CMC/tetracaine transepithelial CXR method (39±3) and uncrosslinked cornea (26±0.9) (P<0.001, Fig. 1).

 
Conclusions:
 

Femtosecond transepithelial CXR triggers less stromal damage but on average an equal amount of corneal density change compared to standard CXL. Permeability enhancer CMC/tetracaine transepithelial CXR is a poor transepithelial permeability enhancer, and triggers minimal apoptosis and no increase in corneal density detected with the GALILEI Scheimpflug Analyzer.  

 
Keywords: keratoconus • photodynamic therapy • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×